Clinical Trial Update: Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin [Phase 3]

View source ↗

Summary

A Phase 3 trial assessed whether paroxetine can prevent depressive syndrome in patients with chronic hepatitis C treated with pegylated interferon alfa plus rib…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Major Depressive Disorder

Drugs mentioned

• Paroxetine (Paroxetine hydrochloride)

Snippet

Sponsor: French National Agency for Research on AIDS and Viral Hepatitis | Conditions: Chronic Hepatitis C | Phase 3 | Status: COMPLETED